key: cord-0734117-ortj91e0 authors: Bandawe, Gama; Chitenje, Moses; Bangoh, Joseph Bitiliyu; Kampira, Elizabeth title: Approaches to deployment of molecular testing for SARS-CoV-2 in resource-limited settings date: 2022-03-01 journal: Clin Lab Med DOI: 10.1016/j.cll.2022.02.008 sha: 8ffe08528c7ba54ec1dc00a659b5bbf07e4903c4 doc_id: 734117 cord_uid: ortj91e0 Deployment of molecular testing for SARS-CoV-2 in resource limited settings is challenging. Scale up of molecular had to be conducted with a laboratory system strengthening approach that emphasise laboratory integration. National reference laboratories play a central role. In Malawi the molecular testing was underpinned by existing pathogen control programs for HIV and TB which use Abbott and GeneXpert machines and reagents. Despite this, the impact on these programs was well managed. Antigen testing increased access to testing. Pooled testing and direct to PCR methods have the potential to save costs and further increase access to molecular tests. Introduction complex machinery, infrastructure and training to conduct competently and routinely with 50 high throughput. The WHO published testing guidelines 4,5,6 which included biosafety level 51 (BSL)-2 conditions for handling of specimens for molecular testing. While these 52 requirements pose a challenge even in the most affluent countries, in resource limited settings 53 they presented an even more significant challenge. Despite this, molecular testing capacity 54 had to be rapidly scaled up to meet the testing needs in every part of the world. Here we 55 outline some of the key considerations, partnerships and activities that were required and 56 draw on several specific examples from Malawi in Southern Africa. Lessons drawn from this 57 experience can be informative for continued laboratory strengthening and preparation for any 58 future outbreaks of novel zoonotic or re-emerging pathogens of public health concern. 59 60 Systems strengthening 61 Low and middle income countries are often those with the highest disease burden and lack of 62 adequate laboratory capacity presents a further barrier in provision of appropriate diagnosis, 63 care and treatment of existing diseases and emerging pathogens 7-9 . The establishment of 64 fully equipped testing laboratories that fulfil WHO guidelines required huge investment, scale up any disease response would need to therefore be conducted using a broader systems 73 strengthening approach that attempts to address many of these issues concurrently. 74 In the last two decades, a significant amount of funding and investment has flowed into 75 strengthening of laboratories 10,11 mainly aligned with specific pathogen control programs was essential. Both of these programs proved to be invaluable in providing a meaningful 85 platform which the deployment of molecular testing for SARS-CoV-2 could build upon. The exigency of using existing infrastructure and capacity to pivot onto the COVID response One of the most important roles spearheaded by the PHL was the coordination of multiple 122 partners in the many activities required to successfully capacitate the health system to 123 conduct high throughput molecular testing and make it as widely available as possible. Table 124 1 gives a snapshot of some of the most important activities undertaken and the partners 125 involved. Alongside the Ministry of Health at least ten different international organisations 126 and regional partners were involved in supporting the various activities under the thematic 127 areas of equipment, infrastructure, personnel, procurement of reagents and consumables, 128 training, sample transportation, data management and quality management. Other key functions of the PHL were decisions on the scale of the diagnostic response, Jack Ma and Alibaba Foundations Donate COVID-19 Medical 431 Equipment to African Union Member States Room-temperature-storable PCR 435 mixes for SARS-CoV-2 detection Implementation of GeneXpert for TB Testing in Low-442 and Middle-Income Countries: A Systematic Review Leveraging polymerase chain reaction 445 technique (GeneXpert) to upscaling testing capacity for SARS-CoV-2 (COVID-19 How COVID hurt the fight against other dangerous diseases Notes from the Field: Impact of the specimens to increase testing capacity for influenza viruses by PCR Evaluation of pooling of samples for testing 524 SARS-CoV-2 for mass screening of COVID-. BMC Infect Dis Evaluation of COVID-19 RT-qPCR Test in Multi 527 sample Pools False-negative 529 results of initial RT-PCR assays for COVID-19: A systematic review Molecular diagnosis for the novel 532 coronavirus SARS-CoV-2 : lessons learnt from the Ghana experience Optimal uses of pooled testing for 535 COVID-19 incorporating imperfect test performance and pool dilution effect: An 536 application to congregate settings in Los Angeles County A pooled testing strategy for identifying 539 SARS-CoV-2 at low prevalence Performance and cost-effectiveness of a 542 pooled testing strategy for SARS-CoV-2 using real-time polymerase chain reaction in doi Laboratory Diagnosis of COVID-19: 546 Current Issues and Challenges SARS-CoV-2 detection by direct rRT-PCR 548 without RNA extraction Evaluation of three extraction-free 551 RT-PCR assays : A feasible alternative approach with low technical 552 requirements Validation of a direct-to-PCR COVID-555 19 detection protocol utilizing mechanical homogenization: A model for reducing 556 resources needed for accurate testing South African Government. SAHPRA approves affordable Coronavirus COVID-19 antigen test Global agencies sign tech transfer deals to boost COVID testing in Africa Development of a transportation system UMB/Riders for Health Successful transportation of 231,850 samples to molecular labs. Transportation from ports of entry and hard to reach areas. Production of case-based surveillance form